Description
Hemadus 50 mg Tablet is an oral medication manufactured by Radiant Pharmaceuticals Ltd. in Bangladesh. It contains Roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. Roxadustat works by inhibiting the HIF-PH enzyme, leading to increased endogenous erythropoietin production and improved iron regulation. This mechanism stimulates erythropoiesis, enhancing red blood cell production and hemoglobin levels. Hemadus is indicated for the treatment of symptomatic anemia associated with chronic kidney disease (CKD), both in patients on dialysis and those not on dialysis. The recommended dosage is 50 mg, administered orally three times per week, with adjustments based on individual patient needs and response to therapy. Common side effects may include hypertension, vascular access thrombosis, diarrhea, peripheral edema, hyperkalemia, and nausea. It is contraindicated in patients with serious infections, liver disorders, or during pregnancy and breastfeeding. Patients should follow their healthcare provider's instructions regarding dosage and administration to ensure optimal therapeutic outcomes
.jpeg)
 1GM.jpeg)
 10MG.jpeg)
60 MG.jpeg)
 20MG.jpeg)
 ..jpeg)
 25MG.jpeg)
 2GM.jpeg)
 ..jpeg)
Change Language